Emerging Norovirus Vaccines Face Scientific, Policy Hurdles

Researchers are advancing several norovirus vaccine candidates, but efficacy, duration of protection, and policy challenges remain.

Mar. 31, 2026 at 9:18am

Got story updates? Submit your updates here. ›

Researchers are making progress on several norovirus vaccine candidates, including oral tablet-based platforms, mRNA vaccines, and virus-like particle technologies. However, the virus's genetic diversity, ability to rapidly mutate, and challenges in growing it in laboratories have slowed vaccine development. Potential efficacy issues, especially in vulnerable populations like older adults and young children, as well as policy and reimbursement hurdles, also present obstacles.

Why it matters

Norovirus is the leading cause of acute gastroenteritis in the U.S., resulting in millions of illnesses, thousands of hospitalizations, and hundreds of deaths annually, especially among older adults, infants, and immunocompromised individuals. An effective vaccine could significantly reduce the global burden of norovirus disease.

The details

Several norovirus vaccine candidates are in various stages of clinical development, including Vaxart's oral tablet vaccine, Moderna's mRNA-based vaccine, and HilleVax's virus-like particle vaccine. Early data has shown these platforms can generate strong mucosal and systemic immune responses. However, challenges remain in achieving broad, cross-genotype protection given the virus's substantial genetic diversity and ongoing evolution. Demonstrating consistent efficacy, especially in high-risk populations, as well as navigating regulatory and reimbursement hurdles, will also be critical for successful vaccine implementation.

  • Norovirus outbreaks are particularly common during the winter months.
  • Vaxart's first-generation oral vaccine reduced acute gastroenteritis by 30% in a Phase 2b human challenge trial.
  • Vaxart's second-generation oral vaccine showed significant improvements, with a 141% increase in serum functional responses and a 25-fold increase in fecal IgA responses compared to the first generation.

The players

Stephanie D. Pointer, MD

A gastroenterologist and co-owner and managing partner of Digestive and Liver Health Specialists in Nashville, Tennessee.

William Schaffner, MD

A professor of infectious diseases at the Vanderbilt University Medical Center in Nashville, Tennessee.

Stephen Goldberg, MD

The chief medical officer of HealthTrackRx, which specializes in outpatient infectious disease diagnostics, and a family medicine physician who also practices urgent care and primary care at UofL Health, affiliated with the University of Louisville School of Medicine in Louisville, Kentucky.

Becca Flitter, PhD

The director of immunology for Vaxart and a lead author of the company's Phase 2b norovirus vaccine trial.

Michael Bass, MD

A gastroenterologist, hepatologist, and the founding director of Oshi Health.

Got photos? Submit your photos here. ›

What they’re saying

“I have been encouraged to see the growing number of norovirus vaccine candidates currently in development.”

— Stephanie D. Pointer, MD, Gastroenterologist

“Although many cases are self-limited, norovirus can cause severe disease in vulnerable populations, including older adults, infants under 12 months of age, and immunocompromised individuals.”

— Stephanie D. Pointer, MD, Gastroenterologist

“We saw a strong mucosal immunity, particularly fecal IgA as well as serum functional antibodies. The phase 2b study demonstrated those were really the most important immune responses elicited by our vaccine that protected individuals from a norovirus challenge.”

— Becca Flitter, PhD, Director of Immunology, Vaxart

“That's a meaningful advantage over an injectable approach that mainly drives serum antibodies and may not generate the same local intestinal defense.”

— Michael Bass, MD, Gastroenterologist and Hepatologist

“Any vaccine will face the challenge of substantial genetic and antigenic diversity. Because norovirus evolves over time — particularly within dominant lineages such as GII.4 — vaccine formulations may need periodic updating, similar in concept to influenza vaccines, although the optimal strategy remains under study.”

— Stephen Goldberg, MD, Chief Medical Officer, HealthTrackRx

What’s next

Vaxart plans to seek partners for larger Phase 2 and 3 trials to further advance its second-generation bivalent norovirus vaccine candidate.

The takeaway

The development of safe and effective norovirus vaccines represents a critical public health priority, as the virus causes significant morbidity and mortality, especially among vulnerable populations. While several promising vaccine candidates are in the pipeline, overcoming scientific, regulatory, and policy hurdles will be essential to bringing a norovirus vaccine to market and reducing the global burden of this disease.